VKTX did a shelf offering yesterday, how come no big price tank? I figured the gods were shorting it at $16 all morning knowing they could buy back at $14. SQ, I bought the $67 calls yesterday at $1.08 ave. SQ was $66.50-$67 when I bought. The $70 calls were like 10,000 contracts.
March 22 Vz you went all negative on me! 3,800 was on the way. Whoops! WHAT SAY YOU NOW!! I do need some of your imput -- and I do value it (when you are being serious) ARE THINGS LOOKING UP! // WILL WE REACH 4,200? marketwatch wants to know.
I know you know the whole SQ story. There was a Hindenberg report Short report. HF got in beginning of week when it sold off. It's a good name. (I think) It fell from $74 area. It was almost $78 prior. Dropped to 58 -- just back of envelope that's $20/divide by 2 = $10 // $10 up from $58 is $68 <-- That's fair value.
This is another insider buy situation i gave you guys. ERAS Erasca, Inc. $2.96 +0.22(+8.03%) NASDAQ |$USD |Pre-Market:$3.12+0.16(+5.41%)<-- On the move again!
Company Profile Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company’s lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; and ERAS-601, an oral SHP2 inhibitor for patients with advanced or metastatic solid tumors. It is also developing ERAS-801, a central nervous system-penetrant EGFR inhibitor for the treatment of patients with recurrent glioblastoma multiforme. The company was incorporated in 2018 and is headquartered in San Diego, California.